JAGUAR HEALTH INC (JAGX) Stock Price, Quote, News and Overview
NASDAQ:JAGX - Nasdaq - US47010C8055 - Common Stock
JAGX Quote and Key Statistics
JAGUAR HEALTH INC
NASDAQ:JAGX (1/21/2025, 8:08:52 PM)
Premarket: 0.8603 +0.02 (+2.37%)0.8404
0 (-0.56%)
JAGX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.55% | ||
| ROE | -234.48% | ||
| Debt/Equity | 1.35 |
JAGX Performance and Technical Analysis
JAGX Ownership and Analysts
JAGX Latest News and Analysis
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
About JAGX
Company Profile
Jaguar Health Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2015-05-13. Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The firm is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. The company operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.
Company Info
JAGUAR HEALTH INC
200 Pine Street Suite 400
San Francisco CALIFORNIA 94104 US
CEO: Lisa A. Conte
Employees: 49
Company Website: https://jaguar.health/
Investor Relations: https://jaguarhealth.gcs-web.com/
Phone: 14153718300
JAGX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 72.99 | 704.73B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.38 | 359.88B | ||
| JNJ | JOHNSON & JOHNSON | 14.47 | 356.69B | ||
| MRK | MERCK & CO. INC. | 16.17 | 243.45B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.84 | 210.75B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.37 | 199.39B | ||
| PFE | PFIZER INC | 10.33 | 150.97B | ||
| SNY | SANOFI-ADR | 12.43 | 129.60B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.75 | 115.69B | ||
| ZTS | ZOETIS INC | 29.09 | 75.58B | ||
| GSK | GSK PLC-SPON ADR | 8.26 | 68.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.83 | 41.53B |